Turnstone Biologics raises US$80 million in Series D financing

Torys acted as counsel to existing investors Versant Ventures, OrbiMed, F-Prime Capital and Sixty Degree Capital with a team that included Cheryl Reicin, Matthew Atkey and Shane Thomas (corporate/life sciences).

On July 21, 2021, Turnstone Biologics Corp. announced the successful completion of an US$80 million Series D financing co-led by PFM Health Sciences and Point72. Additional new investors Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures Inc., CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor were joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.

Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.

Further information can be found on Business Wire’s website.

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading platforms, both independently and in combination, that drive innate and adaptive tumor immunity to provide benefit to the millions of cancer patients underserved by current treatment options.